Evidence map›Paper›PMID 37350478›Full record

ArticleHuman vaccines & immunotherapeutics2023

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration.

Meagan E Miller, Mahvish Q Rahim, Scott L Coven, Seethal A Jacob, Gregory D Zimet, Carolyn G Meagher, Mary A Ott

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Meagan E MillerIndiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0001-8377-6370
Mahvish Q RahimIndiana University School of Medicine, Indianapolis, IN, USA.
Scott L CovenIndiana University School of Medicine, Indianapolis, IN, USA.
Seethal A JacobIndiana University School of Medicine, Indianapolis, IN, USA.
Gregory D ZimetCancer Prevention and Control Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IA, USA.
Carolyn G MeagherDivision of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA.
Mary A OttDivision of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA.
University School · USIndiana University Health · US

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Leveraging Infrastructure to train investigators in patient centered outcomes research in the learning health system (LITI-PCORLHS)K12HS026390 · AHRQ · INDIANA UNIVERSITY INDIANAPOLIS · PI CARROLL, AARON E., EMBI, PETER J. · 2018 to 2022
$3.4M
Telemedicine for Pediatric Sickle Cell Care in Medically Underserved CommunitiesK23HL143162 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI JACOB, SEETHAL · 2021 to 2025
$919k
AHRQ HHS K12 HS026390NCI NIH HHS P30 CA082709NHLBI NIH HHS K23 HL143162
6 · The paper itself

Abstract

Rates of Human papilloma virus (HPV) vaccination among pediatric survivors of cancer and patients with sickle cell disease are lower than the national average. While recent attention has focused on patient HPV vaccine hesitancy and refusal, less is known about provider-level and system-level barriers to vaccinations in pediatric hematology/oncology (PHO) populations. Applying thematic analysis to qualitative interviews with 20 pediatric hematology/oncology physicians and nurse practitioners, we examine their views regarding HPV vaccination, with a focus on access and barriers to providing HPV vaccination in PHO practices. Results demonstrated that despite 90% of interviewees supporting HPV vaccination in their population, the number of pediatric hematology/oncology providers who reported that they counsel about HPV or provide HPV vaccination was 45%, even in stem cell and sickle cell clinics, where other childhood vaccines are commonly provided. Clinicians identified provider-level, clinic-level, and system-level barriers to giving the HPV vaccination, including but not limited to time/flow constraints, lack of resources, and continued education regarding the HPV vaccine. These barriers impede the ability for pediatric hematology/oncology providers to counsel and provide HPV vaccination to this specialized population.

Indexed as

HematologyNurse PractitionersPapillomavirus InfectionsPapillomavirus VaccinesPhysiciansChildHealth Knowledge, Attitudes, PracticeHealth PersonnelHumansVaccinationPapillomavirus Vaccinesbarriershematology/oncologyHuman papilloma viruspediatricsprovider attitudesvaccine

Identifiers

PMID37350478
PMCPMC10291937
OpenAlexW4381716726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.